Lyell Immunopharma
LYEL | NASDAQ
$14.65
+$0.35 (+2.45%)
At close: Nov 16, 2026, 4:00 PM ET
$14.65
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
+2.45%
(1D)No price chart data available for 1D timeframe.
Rating
26.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #874/1021 (Top 86%)
Key Statistics
Market Data
Market Cap $360.18M
1D Range
14.14 14.93
52W Range
7.51 38.60
Valuation (TTM)
PE -1.27
PB 1.87
EV/EBITDA -1.06
Valuation (NTM)
Forward PE N/A
Forward PEG 0.03
Price Target $39.50
Cash Flow
FCF Yield -38.9%
SBC Adj. FCF Yield -48.5%
SBC Impact -24.7%
Margins
Gross Margin -15446.7%
Operating Margin -1044686.7%
FCF Margin -933100.0%
Growth (CAGR)
Revenue 3Y | 5Y -93.2% |
-72.8%
Dil EPS 3Y | 5Y -88.1% |
-65.0%
FCF 3Y | 5Y 5.3% |
6.7%
Returns
ROA -93.2%
ROE -107.6%
ROIC -89.2%
Financial Health
Net Cash
$177.11M
Current Ratio 4.02
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The com...
Sector Healthcare
Industry Biotechnology
Employees 161
IPO Date Jun 17, 2021
Website www.lyell.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 4, 2026
EPS
-$1.86
Beat +2.49%
YoY:
+12.68% REV
$3K
Beat +50.00%
YoY:
-80.00%Next Earnings
Mar 11, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$39.50
Upside
+169.62%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove LYEL